Tag: ONWD

2 articles

Market Moves

ONWARD Medical's spinal stimulator sales stalled in the third quarter

ONWARD Medical reported EUR 2.5 million of revenue for the third quarter of 2026 on 3 November, up from EUR 1.7 million a year earlier, but ARC-EX product revenue of EUR 2.0 million and 88 units were roughly level with the second quarter. The shares closed about 11.5 per cent lower in Brussels and KBC Securities cut its rating to hold.

Nov 5

Market Moves

ONWARD Medical crosses seven ARC-BCI implants as ARC-EX commercial revenue grows 240 percent in H1

Dutch-Swiss neurotech ONWARD Medical (Euronext ONWD) reported First Half 2026 results on 9 September 2026 with total revenue of EUR 4.2 million (up from EUR 1.2 million H1 2025), ARC-EX external spinal-stimulator commercial revenue up 240 percent to EUR 3.4 million, and cumulative ARC-BCI Therapy participants now at seven, with two additional implants completed in the half. ARC-BCI is ONWARD's flagship platform pairing the CEA/Clinatec WIMAGINE 64-electrode epidural cortical brain-computer interface (exclusive-licensed 15 October 2024) with the ARC-IM implantable spinal cord stimulator. ONWARD is accepted into the FDA Total Product Life Cycle Advisory Program for ARC-BCI. Cash position was EUR 81.5 million at 30 June 2026 following the April 2026 EUR 40.6 million equity raise led by EQT Life Sciences and a new BlackRock debt facility up to EUR 50 million. ARC-EX (FDA De Novo cleared December 2024) is now available in more than 130 US clinics and shipped 159 systems in the half.

Sep 10